Medindia
Why Register as Premium Member if you have Hypertension? Click Here
Medindia » Health Watch

Blood Test To Predict Anemia Risk Post Malaria Treatment

by Julia Samuel on July 7, 2017 at 10:55 PM
Listen to this News

Highlights

  • Anemia frequently affects patients treated for severe malaria with artemisinin drugs which kills malarial parasites.
  • But the deparasitized red blood cells retain the parasite histidine-rich protein 2 (HRP2).
  • HRP2 can be measured with a rapid diagnostic dipstick test that then can be used to predict the risk for delayed hemolysis and anemia.
  • An estimated 3.2 billion people in 95 countries are at risk of malaria infection, and even though treatment with a class of drugs called artemisinins is associated with fatality rates lower than 5%, some patients receiving these agents develop severe anemia weeks after clearance of the parasite.


    Researchers have adapted an existing diagnostic test for malaria to predict the dangerous complications that sometimes arise after the parasite is eradicated from patients' blood.

    ‘An existing diagnostic test for malaria predicts the dangerous complications that sometimes arise after the parasite is eradicated from the patients' blood.’

    Clinicians lack reliable methods to pinpoint which patients will experience widespread destruction of their red blood cells following therapy with the artemisinin artesunate - a condition called post-artesunate delayed hemolysis (PADH).

    Episodes of PADH have been linked with severe kidney failure, which is one reason why the World Health Organization has noted an urgent need for a simple and reliable test. Here, Papa Alioune Ndour and colleagues repurposed a diagnostic already in use - the BinaxNOW malaria kit - to predict PADH with 89% sensitivity and 73% specificity.

    The assay measures remnants of a malaria protein named HRP2 on red blood cells, and was successfully validated using diluted blood samples from 95 Bangladeshi patients and 53 French travelers, all of whom received artesunate.

    Notably, a separate cohort of 49 patients that were administered quinine (which is not associated with post-treatment anemia) did not have persistently high HRP2 levels. The authors say the accuracy of the test must be confirmed in larger-scale prospective studies, and may be preferable to current recommendations for mandatory 28-day monitoring of all malaria patients - to help high-risk patients achieve better post-treatment outcomes.

    Facts on Malaria

    Reference

    1. Papa Alioune Ndour et al., Measuring the Plasmodium falciparum HRP2 protein in blood from artesunate-treated malaria patients predicts post-artesunate delayed hemolysis, Science Translational Medicine (2017).


    Source: Medindia

    Cite this Article

    Please use one of the following formats to cite this article in your essay, paper or report:

    • APA

      Julia Samuel. (2017, July 07). Blood Test To Predict Anemia Risk Post Malaria Treatment. Medindia. Retrieved on Jan 23, 2025 from https://www.medindia.net/news/healthwatch/blood-test-to-predict-anemia-risk-post-malaria-treatment-171499-1.htm.

    • MLA

      Julia Samuel. "Blood Test To Predict Anemia Risk Post Malaria Treatment". Medindia. Jan 23, 2025. <https://www.medindia.net/news/healthwatch/blood-test-to-predict-anemia-risk-post-malaria-treatment-171499-1.htm>.

    • Chicago

      Julia Samuel. "Blood Test To Predict Anemia Risk Post Malaria Treatment". Medindia. https://www.medindia.net/news/healthwatch/blood-test-to-predict-anemia-risk-post-malaria-treatment-171499-1.htm. (accessed Jan 23, 2025).

    • Harvard

      Julia Samuel. 2017. Blood Test To Predict Anemia Risk Post Malaria Treatment. Medindia, viewed Jan 23, 2025, https://www.medindia.net/news/healthwatch/blood-test-to-predict-anemia-risk-post-malaria-treatment-171499-1.htm.

    View Non AMP Site | Back to top ↑